A Single-centre, Double-blind, Randomized, Placebo-controlled, Single-ascending Oral Dose and Food Interaction Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-281959 / ACT-246475 in Healthy Male Subjects
Latest Information Update: 07 Nov 2021
At a glance
- Drugs ACT 281959 (Primary) ; Selatogrel (Primary)
- Indications Cardiovascular disorders
- Focus Adverse reactions
- Sponsors Actelion Pharmaceuticals
- 22 Mar 2014 Results presented at the 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 10 Oct 2013 New trial record